Zelira's Zenivol, Clinically Validated Cannabinoid Medication For Insomnia, Gets Regulatory Approval In Germany

Zelira Therapeutics Ltd’s (OTCQB: ZLDAF) (ASX:ZLD) insomnia medication Zenivol has achieved formal approval from German regulatory authority BfArM to launch in the German market.

According to the company, Zenivol is the world's first and only clinically validated, pharmaceutical-grade, cannabis-based sleep medication. Zenivol's clinical research was peer reviewed in the Journal of Sleep. It is currently available by prescription in Australia under the country's legal cannabis regulations.

"The formal approval of Zenivol by BfArM in Germany marks a major milestone for Zelira; Germany is one of the largest global markets for cannabinoid-based medicines, and also one of the highest quality global regulatory markets for pharmaceuticals," stated Zelira CEO Dr. Oludare Odumosu. "We look forward to working with our partner, Adjupharm, …

Full story available on Benzinga.com

Zelira's Zenivol, Clinically Validated Cannabinoid Medication For Insomnia, Gets Regulatory Approval In Germany on Benzinga